Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 510902, 7 pages
http://dx.doi.org/10.1155/2012/510902
Research Article

Circulating TGF-β1, Glycation, and Oxidation in Children with Diabetes Mellitus Type 1

1Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Faculty of Medicine, Comenius University, Sasinkova 2, Bratislava 81108, Slovakia
2Department of Immunology, Faculty of Medicine, Comenius University, Sasinkova 2, Bratislava 81108, Slovakia
3National Institute for Certified Educational Measurements, Žehrianska 9, Bratislava 85107, Slovakia

Received 28 March 2012; Revised 31 July 2012; Accepted 14 August 2012

Academic Editor: Pietro Galassetti

Copyright © 2012 Vladimír Jakuš et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Beisswenger, “Glycation and biomarkers of vascular complications of diabetes,” Amino Acids, vol. 42, no. 4, pp. 1171–1183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Jakuš and N. Rietbrock, “Advanced glycation end-products and the progress of diabetic vascular complications,” Physiological Research, vol. 53, no. 2, pp. 131–142, 2004. View at Google Scholar · View at Scopus
  3. G. Pugliese, “Do advanced glycation end products contribute to the development of long-term diabetic complications?” Nutrition, Metabolism & Cardiovascular Diseases, vol. 18, no. 7, pp. 457–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Kashihara, Y. Haruna, V. K. Kondeti, and Y. S. Kanwar, “Oxidative stress in diabetic nephropathy,” Current Medicinal Chemistry, vol. 17, no. 34, pp. 4256–4269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Y. Goh and M. E. Cooper, “The role of advanced glycation end products in progression and complications of diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 4, pp. 1143–1152, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. J. W. Nin, A. Jorsal, I. Ferreira et al., “Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study,” Diabetes Care, vol. 34, no. 2, pp. 442–447, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. Mosquera, “Role of the receptor for advanced glycation end products (RAGE) in inflammation,” Investigacion Clinica, vol. 51, no. 2, pp. 257–268, 2010. View at Google Scholar · View at Scopus
  8. S. M. Son, “Role of vascular reactive oxygen species in development of vascular abnormalities in diabetes,” Diabetes Research and Clinical Practice, vol. 77, no. 3, pp. S65–S70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Madonna and R. De Caterina, “Cellular and molecular mechanisms of vascular injury in diabetes—Part I: Pathways of vascular disease in diabetes,” Vascular Pharmacology, vol. 54, no. 3–6, pp. 68–74, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. Kuyvenhoven and A. E. Meinders, “Oxidative stress and diabetes mellitus Pathogenesis of long-term complications,” European Journal of Internal Medicine, vol. 10, no. 1, pp. 9–19, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Boizel, G. Bruttmann, P. Y. Benhamou, S. Halimi, and F. Stanke-Labesque, “Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes,” Diabetologia, vol. 53, no. 9, pp. 2068–2070, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Piwowar, “Advanced oxidation protein products. Part II. the significance of oxidation protein products in the pathomechanism of diabetes and its complications,” Polski Merkuriusz Lekarski, vol. 28, no. 165, pp. 227–230, 2010. View at Google Scholar · View at Scopus
  13. S. F. Yan, R. Ramasamy, and A. M. Schmidt, “Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications,” Nature Clinical Practice Endocrinology and Metabolism, vol. 4, no. 5, pp. 285–293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. S. Bargnoux, M. Morena, S. Badiou et al., “Biologie des fonctions renales et de l' insuffisance renale,” Annales De Biologie Clinique, vol. 67, no. 2, pp. 153–158, 2009. View at Google Scholar
  15. S. Maeda, T. Matsui, M. Takeuchi et al., “Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis,” Pharmacological Research, vol. 63, no. 3, pp. 241–248, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Wolf and F. N. Ziyadeh, “Cellular and molecular mechanisms of proteinuria in diabetic nephropathy,” Nephron—Physiology, vol. 106, no. 2, pp. p26–p31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Elmarakby, R. Abdelsayed, J. Y. Liu, and M. S. Mozaffari, “Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathy,” EPMA Journal, vol. 1, no. 1, pp. 117–129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Li, X. R. Huang, H. J. Zhu et al., “Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease,” The FASEB Journal, vol. 18, no. 1, pp. 176–178, 2004. View at Google Scholar · View at Scopus
  19. A. C. K. Chung, H. Zhang, Y. Z. Kong et al., “Advanced glycation end-products induce tubular CTGF via TGF-β-independent Smad3 signaling,” Journal of the American Society of Nephrology, vol. 21, no. 2, pp. 249–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. El-Saadani, H. Esterbauer, M. El-Sayed, M. Goher, A. Y. Nassar, and G. Jurgens, “A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent,” Journal of Lipid Research, vol. 30, no. 4, pp. 627–630, 1989. View at Google Scholar · View at Scopus
  21. V. Witko-Sarsat, M. Friedlander, C. Capeillère-Blandin et al., “Advanced oxidation protein products as a novel marker of oxidative stress in uremia,” Kidney International, vol. 49, no. 5, pp. 1304–1313, 1996. View at Google Scholar · View at Scopus
  22. M. Kalousová, J. Škrha, and T. Zima, “Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus,” Physiological Research, vol. 51, no. 6, pp. 597–604, 2002. View at Google Scholar · View at Scopus
  23. J. Kostolanska, V. Jakus, L. Barak, A. Stanikova, and I. Waczulikova, “Comparative study of serum/plasma glycation and lipid peroxidation of young patients with type 1 diabetes mellitus in relation to glycemic compensation and the occurrence of diabetic complications,” Bratislava Medical Journal, vol. 111, no. 11, pp. 578–585, 2010. View at Google Scholar · View at Scopus
  24. J. Kostolanská, V. Jakuš, L. Barák, and A. Staníková, “Impact of long-term glycemic control on changes of lipid profile in children and adolescents with 1 type diabetes mellitus,” Vnitrni Lekarstvi, vol. 57, no. 6, pp. 533–539, 2011. View at Google Scholar · View at Scopus
  25. D. J. Grainger, D. E. Mosedale, and J. C. Metcalfe, “TGF-β in blood: a complex problem,” Cytokine & Growth Factor Reviews, vol. 11, no. 1-2, pp. 133–145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Szarka, J. Rigó, L. Lázár, G. Beko, and A. Molvarec, “Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array,” BMC Immunology, vol. 11, article 59, pp. 1–9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg, “From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines,” Endocrine Reviews, vol. 25, no. 6, pp. 971–1010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Hefini, A. Kamel, H. El-Banawy et al., “The role of BMP-7 and TGF-beta1 in diabetic nephropathy,” Journal of Medical Research Institute, vol. 28, no. 3, pp. 235–243, 2007. View at Google Scholar
  29. M. van den Heuvel, W. W. Batenburg, and A. H. J. Danser, “Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-β1 axis?” Molecular and Cellular Endocrinology, vol. 302, no. 2, pp. 213–218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. B. D. Schaan, A. S. Quadros, R. Sarmento-Leite, G. De Lucca, A. Bender, and M. Bertoluci, “'Correction:' Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with pre-existent coronary artery disease,” Cardiovascular Diabetology, vol. 6, article 19, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Ibrahim and L. Rashed, “Estimation of transforming growth factor-beta 1 as a marker of renal injury in type II diabetes mellitus,” Saudi Medical Journal, vol. 28, no. 4, pp. 519–523, 2007. View at Google Scholar · View at Scopus
  32. S. Yener, A. Comlekci, B. Akinci et al., “Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone,” Hormones, vol. 7, no. 1, pp. 70–76, 2008. View at Google Scholar · View at Scopus
  33. G. R. Huseynova, G. I. Azizova, and A. M. Efendiyev, “Quantitative changes in serum IL-8, TNF-α and TGF-β1 levels depending on compensation stage in type 2 diabetic patients,” International Journal of Diabetes and Metabolism, vol. 17, no. 2, pp. 59–62, 2009. View at Google Scholar · View at Scopus
  34. S. T. Azar, I. Salti, M. S. Zantout, and S. Major, “Alterations in plasma transforming growth factor β in normoalbuminuric type 1 and type 2 diabetic patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 12, pp. 4680–4682, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Chaturvedi, C. G. Schalkwijk, H. Abrahamian, J. H. Fuller, and C. D. Stehouwer, “Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study,” Diabetes Care, vol. 25, no. 12, pp. 2320–2327, 2002. View at Google Scholar · View at Scopus